CJC-1295 (no DAC) + Ipamorelin
Also known as: CJC / Ipamorelin blend, GHRH + GHS stack
CJC-1295 (no DAC) + Ipamorelin, also called CJC / Ipamorelin blend or GHRH + GHS stack, is a research peptide in the GHRH/GHRP class. This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class.
For research use only.
Key Facts
- CAS
- N/A (blend)
- Molecular Weight (MW)
- Varies
- Half-life
- CJC: ~30 min; Ipa: ~2 hours
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GHRH receptorGHSR (ghrelin receptor)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 37
- Listed offers
- 73
- Median price per mg (peptide vials)
- $5.68/mg
- Typical $4.63–$6.80/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials34 vendors · median $5.68/mg
- Sprays, route not stated3 vendors · $8.70–$10.20/mg
- Other forms2 vendors · $180.00/mg
Research summary
Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's CJC-1295 (no DAC) + Ipamorelin profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
CJC-1295 (no DAC) + Ipamorelin dosage: no established human dose
The CJC-1295 (no DAC) and ipamorelin blend has no established human dosage. No human study has tested the two together. CJC-1295 without DAC has no human study of its own: the published human data is for the longer-acting DAC form, a different molecule. Ipamorelin has been given to people only intravenously, in a pharmacokinetic study and a post-surgery trial.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: The blend pairs a GHRH analogue (CJC-1295 without DAC, also sold as Mod GRF(1-29)) with a ghrelin-receptor agonist (ipamorelin). No study of the two given together was found in PubMed or ClinicalTrials.gov. CJC-1295 without DAC has no indexed human study at all, and ipamorelin's human data is intravenous only, so neither component supplies a dose for this blend.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Component (analog evidence) — CJC-1295 with DAC, a different molecule from the no-DAC form in this blend (Teichman et al., 2006)Clinical trial · Two randomised placebo-controlled ascending-dose trials of the DAC analogue, not the no-DAC componentStudied an analog, not CJC-1295 (no DAC) + Ipamorelin itself | Healthy adults aged 21–61 | One of four ascending single doses, or two or three weekly or biweekly doses; the authors describe 30 or 60 mcg/kg as relatively well tolerated | Subcutaneous | Single dose, or weekly or biweekly | 28 and 49 days | Growth hormone rose 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days after one injection; estimated half-life 5.8–8.1 days | Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. |
| Component (analog evidence) — ipamorelin: human pharmacokinetic study (Gobburu et al., 1999)Clinical trial · Human dose-escalation PK/PD study of one component aloneStudied an analog, not CJC-1295 (no DAC) + Ipamorelin itself | Healthy male volunteers, 8 per dose level | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg of ipamorelin alone (dose escalation) | Intravenous infusion over 15 minutes | Single dose per level | Single 15-minute infusion | Dose-proportional pharmacokinetics, terminal half-life about 2 hours, and a single episode of growth hormone release at every dose | Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. |
| Component (analog evidence) — ipamorelin: phase 2 trial in post-operative ileus (Beck et al., 2014; NCT00672074)Clinical trial · Phase 2 double-blind randomised placebo-controlled trial of one component aloneStudied an analog, not CJC-1295 (no DAC) + Ipamorelin itself | Adults after small or large bowel resection (117 enrolled, 114 analysed) | 0.03 mg/kg of ipamorelin alone | Intravenous infusion | Twice daily | Postoperative day 1 to day 7, or until discharge | No significant difference from placebo in time to first tolerated solid meal (p = 0.15) | Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014. |
Where sources disagree
- A blend's amount of CJC-1295 or ipamorelin is not a dose that was studied for that compound. See the CJC-1295 (no DAC) and Ipamorelin profiles for what each component's evidence shows.
- The CJC-1295 human study used the DAC form, which lasts days rather than minutes. Its doses and dosing interval do not carry over to the no-DAC form sold in this blend.
- Shop listings sell the blend as one total amount, most often 10 mg or 20 mg, and the split between the two components (usually equal) is set by the seller.
Reconstitution
Common research vial sizes: 10 mg, 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL of total blend | 50 mcg of total blend per 0.01 mL |
| 20 mg | 2 mL | 10 mg/mL of total blend | 100 mcg of total blend per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- 3 mL BAC for 6mg/12mg blend
- Injection Sites
- Abdomen
- Concentration Example
- 18 mg / 3 mL = 6 mg/mL
- Timing Notes
- Bedtime/AM
- Expected Onset
- 1-2 weeks
How to reconstitute CJC-1295 (no DAC) + Ipamorelin
- Check the vial size and diluent volume. The profile example for CJC-1295 (no DAC) + Ipamorelin is: 3 mL BAC for 6mg/12mg blend.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 18 mg / 3 mL = 6 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Open the peptide calculator with the CJC-1295 (no DAC) + Ipamorelin preset →
Sequence & molecular data
| Amino acid sequence | CJC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Ipa: Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
|---|---|
| Molecular formula | Varies (blend) |
| Molecular weight | Varies |
| CAS number | N/A (blend) |
| Half-life | CJC: ~30 min; Ipa: ~2 hours |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class. CJC-1295 without DAC binds the GHRH receptor on somatotrophs and raises cyclic AMP, increasing growth hormone synthesis and release, while ipamorelin binds growth hormone secretagogue receptor 1a and additionally reduces hypothalamic somatostatin tone. Because the two receptors converge on growth hormone release through separate signalling routes and somatostatin inhibition is relieved at the same time, the combined effect reported in experimental settings exceeds the sum of either alone. No controlled human trials of this specific blend have been published.
Origin
Combination of two synthetic GH secretagogues.
Targets
Studies
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus (component evidence (ipamorelin))
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism (component evidence (ipamorelin))
Regulatory & research status
CJC-1295 (no DAC) + Ipamorelin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
CJC-1295 (no DAC) + Ipamorelin side effects
CJC-1295 (no DAC) + Ipamorelin has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Flushing
- Headache
- Water retention
Contraindications
- Cancer history
Stacking
Common stacking partners
Combinations that include CJC-1295 (no DAC) + Ipamorelin, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
CJC-1295 (no DAC) + Ipamorelin: frequently asked questions
What is CJC-1295 (no DAC) + Ipamorelin?
Research blend combining a GHRH analog (usually Mod GRF / CJC no DAC) with ipamorelin to stimulate GH via two receptor classes. Not FDA-approved. Both components are WADA S2.
How does CJC-1295 (no DAC) + Ipamorelin work?
This combination pairs a GHRH receptor agonist with a ghrelin receptor agonist, which is pharmacologically distinct from combining two agents of the same class. CJC-1295 without DAC binds the GHRH receptor on somatotrophs and raises cyclic AMP, increasing growth hormone synthesis and release, while ipamorelin binds growth hormone secretagogue receptor 1a and additionally reduces hypothalamic somatostatin tone.
Is CJC-1295 (no DAC) + Ipamorelin FDA approved?
No. CJC-1295 (no DAC) + Ipamorelin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of CJC-1295 (no DAC) + Ipamorelin?
Reported half-life for CJC-1295 (no DAC) + Ipamorelin is CJC: ~30 min; Ipa: ~2 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of CJC-1295 (no DAC) + Ipamorelin?
CJC-1295 (no DAC) + Ipamorelin has the sequence CJC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Ipa: Aib-His-D-2-Nal-D-Phe-Lys-NH2, giving a chain of 36 amino acids. Its molecular formula is Varies (blend).
Is CJC-1295 (no DAC) + Ipamorelin banned in sport?
CJC-1295 (no DAC) + Ipamorelin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
References
- WADA Prohibited List 2026External reference
- Component evidence (Ipamorelin) — The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicusExternal reference
- Component evidence (Ipamorelin) — The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanismExternal reference
Related research, comparisons & guides
- Ipamorelin Dosage: What the Research Reports and How the Vial Math Works
- CJC-1295 and Ipamorelin: Why the Pairing Exists and What the Vial Math Looks Like
- Peptides for Muscle Growth: Separating Mechanism From Evidence
- Ipamorelin vs. Sermorelin: Two Receptors, One Outcome
- CJC-1295 DAC vs No DAC: One Name, Two Different Molecules
- Peptide dosage chart: dose, route and frequencyCategory
- CJC-1295 (no DAC) + Ipamorelin calculator: reconstitution and syringe units
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This CJC-1295 (no DAC) + Ipamorelin profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track CJC-1295 (no DAC) + Ipamorelin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →